BioVie cuts stock offering cap again, this time to $285,000

BioVie Inc. filed Amendment No. 2 to its prospectus supplement on November 4, 2026, further reducing the size of its at-the-market stock offering. The company said it was filing the amendment to cut the amount of common stock it may offer and sell under the Sales Agreement to a new aggregate limit of $285,000.¹

The reduction follows Amendment No. 1, which had already lowered the ceiling once. The latest filing amends the prospectus supplement dated September 11, 2026, and the accompanying prospectus dated June 29, 2026, as previously amended by Amendment No. 1 dated November 4, 2026, which together had covered an offering of up to $1,225,000 in Class A common stock, par value $0.0001 per share, sold through or to A.G.P./Alliance Global Partners acting as sales agent or principal.¹ The underlying sales agreement with A.G.P. is dated September 11, 2026.¹

BioVie's stock trades on Nasdaq. The common stock is listed on The Nasdaq Capital Market under the symbol "BIVI," and on November 4, 2026, the last reported sale price was $1.34 per share.¹

The filing also restated the company's public float figures. As of November 4, 2026, the aggregate market value of BioVie's common stock held by non-affiliates was $17,905,158.45, calculated using 8,649,835 shares held by non-affiliates as of October 31, 2026, priced at $2.07 per share, which was the closing price on September 8, 2026.¹ As of the date of the filing, BioVie had sold roughly $282,958 of shares under Form S-3 General Instruction I.B.6 during the preceding 12 calendar month period.¹

The company reiterated the regulatory limit tied to its float size. Under General Instruction I.B.6 of Form S-3, BioVie will not sell securities in public primary offerings with a value exceeding one-third of its public float in any 12-calendar month period so long as the float stays below $75 million.¹